The EpiSwitch™ OBD27 Breast Cancer Test is a qualitative in vitro diagnostic test detecting markers for changes in chromosomal conformation associated with gene expression from whole blood patient samples, as an adjunct to mammography, ultrasound, biopsy and other clinical findings to aid in the diagnosis of breast cancer. It detects key chromosomal conformations including those in the key breast cancer gene loci of BRCA1, BRCA2, oestrogen receptor, and the progesterone receptor.
Oxford BioDynamics EpiSwitch™ - the OBD27 Breast Cancer Test is indicated for: Female patients <50 years of age considered high risk by family history. Patients with a positive result would undergo mammography/ultrasound screening. It would be recommended that patients with negative results would undergo the OBD27 Testing at repeated intervals.
Potential use of the OBD27 test in breast cancer diagnosis, women 30 – 50 years of age
In female patients >50 years of age concurrent with mammography/ultrasound scans, of which both results would be reviewed by the pathologist to determine next steps in the clinical management of the patient.
Potential use of the OBD27 test in breast cancer diagnosis, women > 50 years of age:
